Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

Angiogenesis

Volumn 19, Issue 3, 2016, Pages 389-406

  MacDonald, Douglas A ^a   Martin, Joel ^a   Muthusamy, Kathir K ^a   Luo, Jiann Kae ^a   Pyles, Erica ^a   Rafique, Ashique ^a   Huang, Tammy ^a   Potocky, Terra ^a   Liu, Yang ^a   Cao, Jingtai ^a   Bono, Françoise ^b   Delesque, Nathalie ^b   Savi, Pierre ^b   Francis, John ^c   Amirkhosravi, Ali ^c   Meyer, Todd ^c   Romano, Carmelo ^a   Glinka, Meredith ^a   Yancopoulos, George D ^a   Stahl, Neil ^a   Wiegand, Stanley J ^a   Papadopoulos, Nicholas ^a   more..

^a REGENERON PHARMACEUTICALS INC   (United States)

^b SANOFI   (France)

^c FLORIDA HOSPITAL   (United States)

Author keywords

Aflibercept; Bevacizumab; Immune complexes; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FC RECEPTOR; FC RECEPTOR IIA; HYBRID PROTEIN; PROTEIN BINDING; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN ANTIBODY COMPLEX; CELL LINE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; IN VITRO STUDY; MACULAR DEGENERATION; METABOLISM; MOUSE; PROTEIN MULTIMERIZATION; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; TRANSGENIC MOUSE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; BEVACIZUMAB; CELL LINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IN VITRO TECHNIQUES; MACULAR DEGENERATION; MICE; MICE, TRANSGENIC; PLATELET ACTIVATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, IGG; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84970990473     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-016-9515-8     Document Type: Article

References (42)

1. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N (1999) VEGF is required for growth and survival in neonatal mice. Development 126(6):1149–1159
2. Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6(9):507–518. doi:10.1038/nrclinonc.2009.110
3. Hauser S, Weich HA (1993) A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9(4):259–268
4. Bressler SB (2009) Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 116(10 Suppl):S1–S7. doi:10.1016/j.ophtha.2009.06.045
5. Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291(15):1900–1901
6. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81(2):154–162
7. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ (1996) Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 80(4):363–366
8. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S (2002) Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133(1):70–77. doi:10.1016/S0002-9394(01)01269-7
9. Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, Do DV, Nguyen QD (2013) Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 4(6):303–309. doi:10.4239/wjd.v4.i6.303
10. Krispel C, Rodrigues M, Xin X, Sodhi A (2013) Ranibizumab in diabetic macular edema. World J Diabetes 4(6):310–318. doi:10.4239/wjd.v4.i6.310
11. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805–2816. doi:10.1056/NEJMoa042760
12. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431. doi:10.1056/NEJMoa054481
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. doi:10.1056/NEJMoa032691
14. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3):363–372. doi:10.1016/j.ophtha.2005.11.019
15. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908. doi:10.1056/NEJMoa1102673
16. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258–1267. doi:10.1016/S0140-6736(13)61501-9
17. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, Schonherr U, Haas A, Ansari-Shahrezaei S, Binder S (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97(3):266–271. doi:10.1136/bjophthalmol-2012-302391
18. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D’Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Muhlbauer B, Puntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 9:CD011230. doi:10.1002/14651858.CD011230.pub2
19. Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203. doi:10.1056/NEJMoa1414264
20. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26(8):859–870. doi:10.1097/01.iae.0000242842.14624.e7
21. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104(47):18363–18370. doi:10.1073/pnas.0708865104
22. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A (2009) Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 7(1):171–181. doi:10.1111/j.1538-7836.2008.03212.x
23. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593–4599
24. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293(4):865–881. doi:10.1006/jmbi.1999.3192
25. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2):171–185. doi:10.1007/s10456-011-9249-6
26. Stoop JW, Zegers BJ, Sander PC, Ballieux RE (1969) Serum immunoglobulin levels in healthy children and adults. Clin Exp Immunol 4(1):101–112
27. Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J (2009) Different properties of VEGF-antagonists: bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 247(12):1601–1608. doi:10.1007/s00417-009-1136-0
28. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99(17):11393–11398. doi:10.1073/pnas.172398299
29. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014) intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121(1):193–201. doi:10.1016/j.ophtha.2013.08.011
30. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113(16):3716–3725. doi:10.1182/blood-2008-09-179754
31. Ma W, Lee SE, Guo J, Qu W, Hudson BI, Schmidt AM, Barile GR (2007) RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci 48(3):1355–1361. doi:10.1167/iovs.06-0738
32. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U, Tubingen Bevacizumab Study G (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48(6):2814–2823. doi:10.1167/iovs.06-1171
33. ®). Invest Ophthalmol Vis Sci 51(13):4954
34. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29(2):95–112
35. Benoit ME, Tenner AJ (2011) Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci 31(9):3459–3469
36. Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS, Aisenbrey S (2013) Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol 97(7):917–923. doi:10.1136/bjophthalmol-2013-303130
37. Klettner A, Recber M, Roider J (2014) Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture. Graefes Arch Clin Exp Ophthalmol 252(10):1593–1598. doi:10.1007/s00417-014-2719-y
38. Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J (2009) Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 247:1601–1608
39. Parker MW, Xu P, Li X, Vander Kooi CW (2012) Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 287(14):11082–11089. doi:10.1074/jbc.M111.331140
40. Wen J, Arakawa T, Philo JS (1996) Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Anal Biochem 240(2):155–166. doi:10.1006/abio.1996.0345
41. Myszka DG (1999) Improving biosensor analysis. J Mol Recognit 12(5):279–284. doi:10.1002/(SICI)1099-1352(199909/10)12:5<279:AID-JMR473>3.0.CO;2-3
42. Cazenave JP, Hemmendinger S, Beretz A, Sutter-Bay A, Launay J (1983) Platelet aggregation: a tool for clinical investigation and pharmacological study. Methodology. Ann Biol Clin (Paris) 41(3):167–179